Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies

EGFR feedback-inhibition by Ran-binding protein 6 is disrupted in cancer

In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells.

MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma

Pharmacological inhibition of p38 MAPK reduces tumor growth in patient-derived xenografts from colon tumors.

Splicing machinery dysregulation drives glioblastoma development/aggressiveness: oncogenic role of SRSF3.

Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL-rearranged AML.